- Home
- CIFRW vs VCEL Comparison
CIFRW vs VCEL Comparison
Compare CIFRW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFRW | VCEL |
|---|---|---|
| Founded | 2020 | 1989 |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | CIFRW | VCEL |
|---|---|---|
| Price | $4.04 | $36.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $60.40 |
| AVG Volume (30 Days) | 67.9K | ★ 592.9K |
| Earning Date | 02-25-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | $152,466,000.00 | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $148.09 |
| Revenue Growth | ★ 76.34 | 14.05 |
| 52 Week Low | $1.58 | $29.24 |
| 52 Week High | $1.69 | $63.00 |
Technical Indicators
Market Signals| Indicator | CIFRW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 44.40 |
| Support Level | $4.59 | $35.85 |
| Resistance Level | $5.13 | $42.68 |
| Average True Range (ATR) | 0.52 | 1.54 |
| MACD | -0.02 | -0.34 |
| Stochastic Oscillator | 1.06 | 9.01 |
Price Performance
Historical ComparisonAbout CIFRW Cipher Mining Inc. Warrant
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.